ExThera Medical Corporation, the leading developer of innovative blood filtering technology to address major global health problems, today announced that the company has closed a Series B financing round with an equity investment led by new investor Fresenius Medical Care Ventures GmbH. The round included existing investors, and the conversion of the company’s convertible note, for a total of $15.3 million. Other terms were not disclosed.
ExThera Medical Corporation, the leading developer of broad- spectrum, dialysis-like devices to treat bloodstream infections, disclosed today that it has been selected to participate in a Phase IV subcontract with the prime contractor for the U.S. Defense Advanced Research Projects Agency’s (DARPA) Dialysis-Like Therapeutics (DLT) program. During pilot Phase II in vivo testing of ExThera’s Seraph® Microbind® Affinity Blood Filter (Seraph), Seraph removed an average of 80±5% (n=4) of methicillin-resistant Staphylococcus aureus (MRSA) in a single pass through the Seraph device.
ExThera Medical Corporation, the leading developer of broad- spectrum, dialysis-like devices to treat bloodstream infections, announced today that it has received approval of its CE mark clinical trial protocol from Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), the German Competent Authority. This approval, together with approval of the Ethics Committee of Hannover Medical School (also received), allows the company to begin its CE mark study in Hannover immediately. In this study Seraph will be used to treat dialysis patients who have Staphylococcus aureus and MRSA bloodstream infections. ExThera conducted a Clinical Site Initiation Meeting at Hannover in November and is awaiting enrollment of its first patient.
ExThera Medical Corporation, a pioneer in the development of broad-spectrum, biomimetic devices for treating life-threatening bloodstream infections, disclosed today that its Seraph® Microbind® Affinity Blood Filter ( Seraph) quickly removed Cytomegalovirus from CMV-spiked whole blood. Study results were presented at the 2015 44th Critical Care Congress of the Society for Critical Care Medicine.
ExThera Medical Corporation has joined a team led by Battelle that is developing a Dialysis-Like Therapeutics (DLT) device to treat sepsis. ExThera plans to work with Battelle and NxStage Medical (NXTM), Inc. on a contract from the Defense Advanced Research Projects Agency, or DARPA, to develop an innovative, new medical device.
ExThera Medical Corporation, a pioneer in the development of broad-spectrum, dialysis-like therapeutic devices to treat life-threatening bloodstream infections, disclosed today that its Seraph® Microbind® Affinity Blood Filter (Seraph) removed 99.9% of two Carbapenem-Resistant Enterobacteriaceae (‘CRE Superbugs’) — E. coli and Klebsiella pneumoniae — from blood samples spiked with the bacteria in just brief contact with the Seraph adsorption media. Study results are published in the online journal PLOS ONE.
ExThera Medical Corporation announced today that it has completed a $3.75 million first closing of its $7 million convertible note offering. This funding will support the completion of the first clinical trial, and commercialization of the company’s Seraph® Microbind® Affinity Blood Filter (Seraph).
U.S. Patent No. 8,758,286 issues to ExThera Medical, whose Seraph® technology is designed to combat drug-resistant ‘superbugs’
ExThera Medical’s Seraph® Microbind® Affinity Blood Filter – An Investigational Device-Based Therapy for the Treatment of Bloodstream Infections